Abstract. Peony is often used in Chinese herbal medicine for the treatment of depression-like disorders. Our previous studies have demonstrated that the total glycosides of peony exert antidepressant-like effects in animal models. Paeoniflorin is the main active glycoside of peony. The aim of this study was to evaluate the antidepressant-like effects of paeoniflorin in mice, as well as its active mechanisms. The results revealed that intraperitoneally injected paeoniflorin significantly reduced the duration of immobility in forced swimming and tail suspension tests. The doses that affected the immobility response did not affect locomotor activity. Furthermore, paeoniflorin antagonized reserpine-induced ptosis, akinesia and hypothermia. Paeoniflorin also significantly increased the levels of serotonin (5-HT) and its metabolite 5-hydroxyindoleacetic acid (5-HIAA) in the hippocampus. These results suggest that the upregulation of serotonergic systems may be an important mechanism for the antidepressant-like effects of paeoniflorin in mice.

Introduction

Depression is a commonly occurring, debilitating and life-threatening psychiatric disorder. Various antidepressants, including tricyclic antidepressants, monoamine oxidase inhibitors and noradrenaline (NA) reuptake inhibitors, are widely available in the pharmaceutical market. However, the majority of these antidepressants have undesirable side-effects (1-3). Consequently, new antidepressants are sought. The root of Paeonia lactiflora Pall. (Ranunculaceae), commonly known as peony, is a commonly used in herbal medicines in China, Korea and Japan. It is a component herb of numerous traditional formulae, including Jiaweiisinisan and Dang Gui Shao Yao San, prescribed for the treatment of depression-like disorders (4,5). The antidepressant-like effect of the total glycoside fraction of peony has also been observed in mice exposed to chronic unpredictable stress (6). Paeoniflorin, the main and active component of peony, has been widely studied as an antioxidant, anticonvulsant, antithrombotic agent, cognition enhancer or learning impairment-attenuating agent and neuroprotecting agent (7-13). However, there is no information available regarding the antidepressant activity of paeoniflorin following intraperitoneal injection in mice (14). In the present study, we assessed the antidepressant-like effects of paeoniflorin and its mechanisms by means of behavioural and pharmacological procedures.

Materials and methods

Animals. Male Institute of Cancer Research (ICR) mice (18-22 g) were obtained from the Laboratory Animal Unit of Zhejiang Chinese Medicine University (Zhejiang, China). The animals were housed five per cage and acclimatized to a colony room with controlled ambient temperature (24±1˚C), humidity (50±10%) and a 12 h light/dark cycle. They were fed a standard diet and water ad libitum and were left to acclimate for 4 days before use in experiments. The use of experimental mice was approved by the Animal Experimentation Ethics Committee of the Zhejiang Chinese Medicine University and conducted in accordance with the National Institutes of Health (NIH) Principles of Laboratory Animal Care (publication No. 80-23, revised 1996).

Drugs. Paeoniflorin (purity >98%) was purchased from Guizhou Dida Technology Co., Ltd. (Zhejiang, China). Imipramine hydrochloride was purchased from Sigma-Aldrich (St. Louis, MO, USA) as a positive control. Reserpine was purchased from Bangmin (Guangzhou, China) and 5-hydroxytryptamine (5-HT), NA, dopamine (DA) and 5-hydroxyindoleacetic acid (5-HIAA) were purchased from Sigma-Aldrich. For intraperitoneal injection, paeoniflorin, imipramine and reserpine were separately dissolved in 0.9% normal saline and were used for 4 days before use in experiments. The use of experimental mice was approved by the Animal Experimentation Ethics Committee of the Zhejiang Chinese Medicine University and conducted in accordance with the National Institutes of Health (NIH) Principles of Laboratory Animal Care (publication No. 80-23, revised 1996).

Tail suspension test. The tail suspension test was based on the method of Steru et al (15). Animals were suspended 50 cm above the floor by means of an adhesive tape, placed ~1 cm
from the tip of the tail. The duration of immobility was recorded during the last 4 min of the 6-min testing period. Mice were considered immobile only when they hung passively and completely motionless.

**Forced swimming test.** The forced swimming test was similar to those described previously (16,17). The mice were individually placed into glass cylinders (height, 25 cm; diameter, 10 cm) containing 10 cm of water (22±1°C). The duration of immobility was defined as the time the mouse spent without struggling, floating motionless or making only small movements necessary to keep its head above water for the 6-min period. The water was exchanged following each trial.

**Locomotor activity.** Locomotor activity was studied using an open-field test which was performed on mice using a slightly modified method (18,19). Briefly, the locomotor activity of the mice was measured using a box (30x30x15 cm) with the floor divided into 25 squares illuminated with light from the ceiling. Mice were placed in the central square and the total number of squares entered was recorded for 2 min. The open field arena was cleaned following each trial.

**Tests of reserpine-induced ptosis, akinesia and hypothermia.** The tests of reserpine-induced ptosis, akinesia and hypothermia were in accordance with those of Bourin et al (20). The mice were treated with reserpine (2.5 mg/kg, i.p.) 10 min after the administration of paeoniflorin. Three parameters of akinesia, the degree of palpebral ptosis and the rectal temperature were recorded at 1 h, 1 h and 4 h, respectively, after the administration of reserpine. The degree of palpebral ptosis was evaluated according to the following rating scale: 0, eyes open; 1, eyes one-quarter closed; 2, eyes half closed; 3, eyes three-quarters closed and 4, eyes completely closed. To measure akinesia, mice were placed in the center of a circle (diameter, 7.5 cm). The total time the mice remained within the circle during a 1-min period was counted.

**Monoamine neurotransmitter assay.** Levels of 5-HT, NA, DA and 5-HIAA in the hippocampus were measured by high-performance liquid chromatography (HPLC) coupled with an electrochemical detector as described previously (4). Briefly, each frozen tissue sample was homogenized in 0.4 M perchloric acid (solution A). The homogenate was stored on ice for 1 h and then centrifuged at 12,000 x g (4°C) for 20 min. The pellet was discarded. A 160-µl aliquot of the supernatant was added to 80 µl solution B [(containing 0.2 M potassium citrate, 0.3 M dipotassium hydrogen phosphate and 0.2 M ethylenediamine tetraacetic acid (EDTA)]. The mixture was stored on ice for 1 h and then centrifuged at 12,000 x g (4°C) for 20 min. Then, 20 µl of the resultant supernatant was directly injected into an ESA liquid chromatography system equipped with a reversed-phase C18 column (150x4.6 mm, 5 µm) and an electrochemical detector (ESA CoulArray, Chelmsford, MA, USA). The detector was set at 450 mV. The mobile phase consisted of 125 mM citric acid-sodium citrate (pH 4.3), 0.1 mM EDTA, 1.2 mM sodium octanesulfonate and 16% methanol. The flow rate was 1.0 ml/min. NA, 5-HT, DA and 5-HIAA were identified and quantified by comparing their retention times and peak areas to those of standard solutions.

The contents of 5-HT, NA, DA and 5-HIAA were expressed as ng/g in wet weight tissue.

**Statistical analysis.** The results were expressed as the mean ± standard error of the mean. All data were analyzed statistically using one-way analysis of variance, followed by Dunnett’s test. P<0.05 was considered to indicate a statistically significant difference.

**Results**

**Paeoniflorin decreases the duration of immobility in the tail suspension test.** Paeoniflorin at doses of 20 and 40 mg/kg significantly decreased the duration of immobility in the tail
suspension test compared with the control group (P<0.05). Imipramine (10 mg/kg) treatment also had a significant effect on immobility (P<0.01; Fig. 1).

Paeoniflorin decreases the duration of immobility in the forced swimming test. Paeoniflorin (40 mg/kg) significantly inhibited immobility in the forced swimming test (P<0.05). Imipramine (10 mg/kg) treatment also decreased the duration of immobility (P<0.01; Fig. 2).

Paeoniflorin has no effect on locomotor activity. The effect of paeoniflorin on the locomotor activity of mice is shown in Fig. 3. Neither paeoniflorin nor imipramine affected locomotor activity at the doses that significantly reduced the immobility response in the tail suspension and forced swimming tests.

Paeoniflorin attenuates reserpine-induced ptosis, akinesia and hypothermia. The effects of paeoniflorin on reserpine-induced ptosis, akinesia and hypothermia are shown in Table I. The paeoniflorin treatment at doses of 20 and 40 mg/kg significantly decreased the scores of reserpine-induced ptosis (P<0.01). The paeoniflorin treatment at 40 mg/kg significantly reduced the time of reserpine-induced akinesia (P<0.05) and significantly antagonized reserpine-induced hypothermia compared with vehicle treatment (P<0.05). Imipramine at a dose of 10 mg/kg significantly antagonized the hypothermia, ptosis and akinesia induced by reserpine (P<0.05, P<0.01 and P<0.05, respectively).

Paeoniflorin increases the concentrations of monoamine neurotransmitters and a major metabolite of 5-HT in the hippocampus. The effect of paeoniflorin on hippocampal monoamine neurotransmitters and a major metabolite of 5-HT in mice is presented in Fig. 4. Paeoniflorin (40 mg/kg) treatment significantly increased the concentration of 5-HIAA and 5-HT in the hippocampus (P<0.01) compared with vehicle treatment, while imipramine treatment significantly affected hippocampal NA, 5-HIAA, DA and 5-HT concentrations (P<0.05, P<0.01, P<0.05 and P<0.01, respectively).

Discussion

The tail suspension and forced swimming tests are widely used for the screening of antidepressant activity (16,18). The forced swimming and tail suspension-induced state of immobility in animals is similar to human depression and is amenable to reversal by antidepressant drugs (16,18). These animal models are based on the despair or helpless behaviour to an inescapable and confined space in animals. The present results demonstrated that paeoniflorin induces significant antidepressant-like effects in these models. The decrease in immobility time was dose-dependent in two models.

In these behavioural tests, false-positive results are occasionally obtained for agents that stimulate locomotor activity (21). Therefore, we determined whether paeoniflorin has excitatory or inhibitory actions on the central nervous system. In our study, paeoniflorin had no effect on the spontaneous locomotor activity of mice, indicating that paeoniflorin had no excitatory or inhibitory action on the central nervous system in effective doses, which eliminates the probability of false-positive results in the tail suspension and forced swimming tests. This finding suggests that the reduction of immobility time elicited by paeoniflorin treatment in the tail suspension and forced swimming tests is likely to be due to a psychomotor-stimulant effect and not a psychomotor-stimulant action.

Table I. Antagonism of paeoniflorin on the reserpine-induced ptosis, akinesia and hypothermia in mice.

| Treatment          | Rectal temperature (˚C) | Scores of ptosis | Akinesia (sec) |
|--------------------|-------------------------|------------------|---------------|
| Vehicle            | 32.00±0.0               | 3.5±0.7          | 60.0±0        |
| Paeoniflorin (10 mg/kg) | 32.05±0.2             | 3.5±0.5          | 54.8±17       |
| Paeoniflorin (20 mg/kg) | 32.03±0.1             | 2.1±1.3          | 43.0±27       |
| Paeoniflorin (40 mg/kg) | 32.07±0.1             | 2.0±1.3          | 32.4±29       |
| Imipramine (10 mg/kg)  | 34.94±0.6              | 0.7±0.8          | 32.3±23       |

Values are the mean ± standard error of the mean (SEM) with 10 mice in each group. Data analysis was performed using Dunnett’s test. *P<0.05 and **P<0.01 vs. the vehicle control group.

Figure 4. Effects of paeoniflorin on monoamine neurotransmitters and a major metabolite of 5-HT in the hippocampus. Values are the mean ± standard error of the mean (SEM) with 8 mice in each group. Data analysis was performed using Dunnett’s test. *P<0.05 and **P<0.01 vs. the vehicle control group. NA, noradrenaline; 5-HIAA, 5-hydroxyindoleacetic acid; DA, dopamine; 5-HT, 5-hydroxytryptamine.
Reserpine is an antihypertensive drug that depletes neuronal storage granules of biogenic amines in the brains of rodents and produces a clinically significant depression-like state (22). Mice become hypothermic, akinetic and diaphoretic, with eyelid drooping, in response to reserpine. Reserpine irreversibly inhibits the vesicular uptake of monoamine neurotransmitters, including NA, DA and 5-HT (21,23). The symptoms are reversed by major classes of antidepressant drugs. The results obtained in the present study demonstrate that paeoniflorin dose-dependently antagonizes the ptosis, akesies and hypothermia induced by reserpine in mice, which indicates that paeoniflorin has an antidepressant-like effect and may have an effect on monoamine neurotransmitters. We then explored the antidepressant mechanism of paeoniflorin by determining the levels of monamine neurotransmitters in the hippocampus by HPLC-electrochemical detection (ECD). The results revealed that paeoniflorin increased the levels of monoamine neurotransmitters in the mouse hippocampus. This observation suggests that the antidepressant-like effects of paeoniflorin may be caused by the preservation of monoamine neurotransmitters.

In a conclusion, upregulation of serotonergic systems may be an important mechanism in the antidepressant-like effects of paeoniflorin in mice.

Acknowledgements

This study was supported by the Zhejiang Provincial Natural Science Foundation of China (Y2101288).

References

1. Shen JW and Liang ZJ: Advances in research on biological etiology of depression and the antidepressants. Pharmacuet Care Res 7: 94-99, 2007.
2. Mandrioli R, Mercolini L, Saracino MA and Raggi MA: Selective serotonin reuptake inhibitors (SSRIs): therapeutic drug monitoring and pharmacological interactions. Curr Med Chem 19: 1846-1863, 2012.
3. Park SW, Kim YK, Lee JG, Kim SH, Kim JM, et al: Antidepressant-like effects of the traditional Chinese medicine kami-shoyo-san in rats. Psychiatry Clin Neurosci 61: 401-406, 2007.
4. Huang Z, Mao QQ, Zhong XM, Li ZY, Qiu FM and Ip SP: Mechanistic study on the antidepressant-like effect of danggui-shaoyao-san, a chinese herbal formula. Evid Based Complement Alternat Med 2012: 173565, 2012.
5. Xie ZL and Wang XH: Clinical study of Jiawei Sini Decoction in the treatment of 38 dysthymic patients. Chin J Inf TCM 12: 8-9, 2005.
6. Mao QQ, Ip SP, Ko KM, Tsai SH, Xian YF and Che CT: Effects of peony glycosides on mice exposed to chronic unpredictable stress: further evidence for antidepressant-like activity. J Ethnopharmacol 124: 316-320, 2009.
7. Ye J, Duan H, Yang X, Yan W and Zheng X: Anti-thrombosis effect of paeoniflorin: evaluated in a photochemical reaction thrombosis model in vivo. Planta Med 67: 766-767, 2001.
8. Xiao L, Wang YZ, Liu J, Luo XT, Ye Y and Zhu XZ: Effects of paeoniflorin on the cerebral infarction, behavioral and cognitive impairments at the chronic stage of transient middle cerebral artery occlusion in rats. Life Sci 78: 413-420, 2005.
9. Zhong SZ, Ge QH, Li Q, Qu R and Ma SP: Peoniflorin attenuates Abeta(1-42)-mediated neurotoxicity by regulating calcium homeostasis and ameliorating oxidative stress in hippocampus of rats. J Neurol Sci 280: 71-78, 2009.
10. Mao QQ, Huang Z, Ip SP and Che CT: Antidepressant-like effect of ethanol extract from Paeonia lactiflora in mice. Phytother Res 22: 1496-1499, 2008.
11. Mao QQ, Ip SP, Ko KM, Tsai SH, Zhao M and Che CT: Peony glycosides protect against corticosterone-induced neurotoxicity in PC12 cells. Cell Mol Neurobiol 29: 643-647, 2009.
12. Mao QQ, Xian YF, Ip SP, Tsai SH and Che CT: Protective effects of peony glycosides against corticosterone-induced cell death in PC12 cells through antioxidant action. J Ethnopharmacol 133: 1121-1125, 2011.
13. Mao QQ, Zhong XM, Qiu FM, Li ZY and Huang Z: Protective effects of paeoniflorin against corticosterone-induced neurotoxicity in PC12 cells. Phytother Res 26: 969-973, 2012.
14. Mao QQ, Ip SP, Xian YF, Hu Z and Che CT: Anti-depressant-like effect of peony: a mini-review. Pharm Biol 50: 72-77, 2012.
15. Steru L, Chernet R, Thierry B and Simon P: The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology (Berl) 85: 367-370, 1985.
16. Yin C, Gou L, Liu Y, Yin X, Zhang L, Jia G and Zhuang X: Antidepressant-like effects of L-theanine in the forced swim and tail suspension tests in mice. Phytother Res 25: 1636-1639, 2011.
17. Sánchez-Mateo CC, Bonkanka CX, Prado B and Rabanal RM: Antidepressant activity of some Hypericum reflexum L. fil. extracts in the forced swimming test in mice. J Ethnopharmacol 112: 115-121, 2007.
18. Gorsolt RD, Bertin A and Jalilfe M: Behavioral despair in mice: a primary screening test for antidepressants. Arch Int Pharmacodyn Ther 229: 327-336, 1977.
19. Nesterova YV, Povetiewa TN, Suslov NI, Semenov AA and Pushkarshkiy SV: Antidepressant activity of diterpene alkaloids of Aconitum baicalense Turcz. Bull Exp Biol Med 151: 425-429, 2011.
20. Bourin M, Poncelet M, Chernet R and Simon P: The value of the reserpine test in psychopharmacology. Arzneimittelforschung 33: 1173-1176, 1983.
21. Bourin M, Fiocco AJ and Clenet F: How valuable are animal models in defining antidepressant activity? Hum Psychopharmacol 16: 9-21, 2001.
22. Mao QQ and Huang Z: Antidepressant drugs and animal models of depression. Foreign Med Sci 32: 216-220, 2005.
23. Dhingra D and Sharma A: Antidepressant-like activity of Glycyrrhiza glabra L. in mouse models of immobility tests. Prog Neuropsychopharmacol Biol Psychiatry 30: 449-454, 2006.